A Study of SPY002-091 in Healthy Volunteers

Launched by SPYRE THERAPEUTICS, INC. · Nov 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called SPY002-091 to see how safe it is and how the body processes it in healthy volunteers. This is the first time this medication is being tested in humans, and researchers want to find out if it can be tolerated well and how it behaves in the body after a single dose. The trial is currently looking for healthy men and women aged 18 to 65 who can commit to attending several visits at the study site.

Participants in this study can expect to stay at the research unit for a short time to receive the medication and will be monitored closely for their health and any side effects. It's important for potential volunteers to be in good health, without any major medical issues, and to avoid using drugs or alcohol that could affect the study. If you meet these criteria and are interested in helping advance medical research, this trial may be a good opportunity for you!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy men and women
• • Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
• Exclusion Criteria:
• • Participation in more than one cohort
• • Evidence of clinically significant abnormality or disease
• • Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
• • History of severe allergic reactions or hypersensitivity
• • Donation or loss of \>1 unit of whole blood within 1 month prior to dosing